JAK2 and myeloproliferative neoplasm: HDAC11 inhibition has been suggested to overcome therapy resistance in lung cancer models, and while its role in resistance to targeted therapies such as approved JAK2 inhibitors in MPN is unknown, current data suggest potential for the combination of JAK2 inhibition and HDAC11 inhibition as a possible future therapeutic strategy (136).